Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Fraser Palamara discusses the successful start Imricor Medical Systems (ASX:IMR) has seen for its trial in treating irregular heart rhythm patients.

The company is currently testing its namesake technology across the United States and Europe, with an early tick of approval coming out of Paris this week.

Tune in to get the latest.

 

While Imricor is a Stockhead advertiser, it did not sponsor this content.

Read MoreBiotechHealth

Featured Companies

You might be interested in